Von Hoff D D, Sarosy G, Brown T D, Kuhn J G, Kisner D L
Semin Oncol. 1986 Sep;13(3 Suppl 2):72-7.
A human tumor cloning system was utilized to screen for the antitumor activity of recombinant interferon alfa-2b (Intron A) alone and in combination with standard antineoplastic agents. These in vitro studies confirmed synergistic effects of alfa-2b plus doxorubicin against primary human tumors. Based on those in vitro findings, a phase I study has been conducted by Sarosy and colleagues that demonstrated that recombinant interferon alpha-2b and doxorubicin could be given together. Myelosuppression was the dose-limiting toxicity. Because responses were noted in the phase I trials with the combination, phase II trials of the combination are warranted. Additional phase I studies that should be pursued include recombinant interferon alpha-2b plus 5-fluorouracil, interferon plus cisplatinum, and interferon plus DTIC.
利用一种人类肿瘤克隆系统来筛选重组干扰素α-2b（Intron A）单独以及与标准抗肿瘤药物联合使用时的抗肿瘤活性。这些体外研究证实了α-2b加阿霉素对原发性人类肿瘤具有协同作用。基于这些体外研究结果，萨罗西及其同事开展了一项I期研究，该研究表明重组干扰素α-2b和阿霉素可以联合使用。骨髓抑制是剂量限制性毒性。由于在I期试验中观察到联合用药有反应，因此有必要进行联合用药的II期试验。应该进行的其他I期研究包括重组干扰素α-2b加5-氟尿嘧啶、干扰素加顺铂以及干扰素加达卡巴嗪。
